Free Trial

Quince Therapeutics (QNCX) Short Interest Ratio & Short Volume

Quince Therapeutics logo
$1.40 -0.05 (-3.45%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$1.41 +0.01 (+1.00%)
As of 02/21/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics Short Interest Data

Quince Therapeutics (QNCX) has a short interest of 2.65 million shares, representing 7.99% of the float (the number of shares available for trading by the public). This marks a 1.92% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.1, indicating that it would take 12.1 days of the average trading volume of 127,744 shares to cover all short positions.

Current Short Interest
2,650,000 shares
Previous Short Interest
2,600,000 shares
Change Vs. Previous Month
+1.92%
Dollar Volume Sold Short
$4.27 million
Short Interest Ratio
12.1 Days to Cover
Last Record Date
January 31, 2025
Outstanding Shares
44,000,000 shares
Float Size
33,180,000 shares
Short Percent of Float
7.99%
Today's Trading Volume
44,281 shares
Average Trading Volume
127,744 shares
Today's Volume Vs. Average
35%
Short Selling Quince Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Quince Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

QNCX Short Interest Over Time

QNCX Days to Cover Over Time

QNCX Percentage of Float Shorted Over Time

Quince Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/20252,650,000 shares $4.27 million +1.9%8.0%12.1 $1.61
1/15/20252,600,000 shares $4.58 million +8.3%7.9%4.4 $1.76
12/31/20242,400,000 shares $4.49 million +0.4%7.3%4.2 $1.87
12/15/20242,390,000 shares $4.85 million +10.1%7.3%4.3 $2.03
11/30/20242,170,000 shares $4.45 million +21.2%6.7%4 $2.05
11/15/20241,790,000 shares $3.19 million -23.8%5.5%3.4 $1.78
10/31/20242,350,000 shares $3.81 million +23.0%7.3%4.2 $1.62
10/15/20241,910,000 shares $1.48 million -0.5%6.0%7.1 $0.77
9/30/20241,920,000 shares $1.49 million -2.0%6.0%12 $0.78
9/15/20241,960,000 shares $1.44 million -5.8%6.1%12.3 $0.74
8/31/20242,080,000 shares $1.44 million +7.8%6.5%12.7 $0.69
8/15/20241,930,000 shares $1.04 million -1.5%6.0%11.6 $0.54
7/31/20241,960,000 shares $1.47 million -5.8%6.1%21.5 $0.75
7/15/20242,080,000 shares $1.56 million -11.9%6.5%21.2 $0.75
6/30/20242,360,000 shares $1.77 million +1.3%7.3%22.1 $0.75
6/15/20242,330,000 shares $1.65 million +13.7%7.2%21.5 $0.71
5/31/20242,050,000 shares $1.70 million +3.0%6.4%21.8 $0.83
5/15/20241,990,000 shares $1.81 million +1.0%6.2%22.6 $0.91
4/30/20241,970,000 shares $2.11 million +5.9%6.6%26.7 $1.07
4/15/20241,860,000 shares $1.87 million No Change6.2%26.8 $1.01
3/31/20241,860,000 shares $1.97 million No Change6.2%26.9 $1.06
3/15/20241,860,000 shares $2.16 million -2.1%6.3%26.4 $1.16
2/29/20241,900,000 shares $2.47 million No Change6.4%22.6 $1.30
2/15/20241,900,000 shares $2.47 million No Change6.4%20.3 $1.30
1/31/20241,900,000 shares $2.36 million -7.3%6.0%20.9 $1.24
1/15/20242,050,000 shares $2.81 million -8.1%6.4%23.2 $1.37
12/31/20232,230,000 shares $2.34 million +16.2%6.9%29.1 $1.05
12/15/20231,920,000 shares $2.27 million -10.7%6.0%18.8 $1.18
11/30/20232,150,000 shares $1.91 million -1.4%6.2%23.2 $0.89
11/15/20232,180,000 shares $1.94 million +0.9%6.3%24 $0.89
10/31/20232,160,000 shares $2.10 million -8.1%6.5%20.3 $0.97
10/15/20232,350,000 shares $2.33 million +0.4%8.3%16.1 $0.99
9/30/20232,340,000 shares $2.62 million -2.1%8.2%7.7 $1.12
9/15/20232,390,000 shares $2.99 million -1.7%8.5%8.6 $1.25
8/31/20232,430,000 shares $3.18 million -6.5%8.6%8.7 $1.31
8/15/20232,600,000 shares $3.30 million -9.7%9.2%9.3 $1.27
7/31/20232,880,000 shares $3.46 million -10.8%10.0%10.5 $1.20
7/15/20233,230,000 shares $5.26 million No Change11.5%12.3 $1.63
6/30/20233,230,000 shares $4.86 million -0.9%11.3%23.8 $1.51
6/15/20233,260,000 shares $4.89 million +2.5%11.4%15.3 $1.50
Secret financial plot unfolding in Washington DC… [DEVELOPING] (Ad)

What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. You see, I’ve recently uncovered a secret financial plot unfolding in Washington DC…

So please take a moment to watch it now.
5/31/20233,180,000 shares $4.77 million +5.3%11.1%2.9 $1.50
5/15/20233,020,000 shares $4.65 million No Change10.6%2.7 $1.54

QNCX Short Interest - Frequently Asked Questions

What is Quince Therapeutics' current short interest?

Short interest is the volume of Quince Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 2,650,000 shares of QNCX short. 7.99% of Quince Therapeutics' shares are currently sold short. Learn More on Quince Therapeutics' current short interest.

What is a good short interest ratio for Quince Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. QNCX shares currently have a short interest ratio of 12.0. Learn More on Quince Therapeutics's short interest ratio.

Which institutional investors are shorting Quince Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Quince Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Quince Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.99% of Quince Therapeutics' floating shares are currently sold short.

Is Quince Therapeutics' short interest increasing or decreasing?

Quince Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,650,000 shares, an increase of 1.9% from the previous total of 2,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Quince Therapeutics' float size?

Quince Therapeutics currently has issued a total of 44,000,000 shares. Some of Quince Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Quince Therapeutics currently has a public float of 33,180,000 shares.

How does Quince Therapeutics' short interest compare to its competitors?

7.99% of Quince Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Quince Therapeutics: UroGen Pharma Ltd. (26.27%), 4D Molecular Therapeutics, Inc. (16.01%), Design Therapeutics, Inc. (10.06%), C4 Therapeutics, Inc. (10.48%), Cardiff Oncology, Inc. (20.44%), Organigram Holdings Inc. (3.01%), Lifecore Biomedical, Inc. (7.52%), Compugen Ltd. (1.58%), Larimar Therapeutics, Inc. (7.95%), Amarin Co. plc (4.10%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

What does it mean to sell short Quince Therapeutics stock?

Short selling QNCX is an investing strategy that aims to generate trading profit from Quince Therapeutics as its price is falling. QNCX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Quince Therapeutics?

A short squeeze for Quince Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of QNCX, which in turn drives the price of the stock up even further.

How often is Quince Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including QNCX, twice per month. The most recent reporting period available is January, 31 2025.




This page (NASDAQ:QNCX) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners